<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Levin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most patients who undergo coronary artery bypass graft (CABG) surgery receive at least one saphenous vein graft (SVG) in addition to one or more arterial grafts. Compared to arterial grafts, vein grafts have a relatively high rate of clinically important stenosis at 5 and 10 years  (<a class="graphic graphic_movie graphicRef61140" href="/d/graphic/61140.html" rel="external">movie 1</a>). (See  <a class="medical medical_review" href="/d/html/1554.html" rel="external">"Coronary artery bypass graft surgery: Graft choices", section on 'Vein grafts'</a>.)</p><p>This topic will discuss issues related to the prevention, clinical presentation, and management of SVG stenosis. The risk factors for and rates of graft failure and long-term outcomes after CABG are discussed separately. (See  <a class="medical medical_review" href="/d/html/1554.html" rel="external">"Coronary artery bypass graft surgery: Graft choices"</a> and  <a class="medical medical_review" href="/d/html/1588.html" rel="external">"Late recurrent angina pectoris after coronary artery bypass graft surgery"</a> and  <a class="medical medical_review" href="/d/html/90757.html" rel="external">"Coronary artery bypass graft surgery: Long-term clinical outcomes"</a>.) </p><p class="headingAnchor" id="H854471874"><span class="h1">STENOSIS VERSUS OCCLUSION</span><span class="headingEndMark"> — </span>Vein graft stenosis implies there is still flow in the graft and that revascularization is technically possible.</p><p>The phrase "vein graft occlusion" implies the graft is 100 percent closed (occluded). Ordinarily, this means there is no option for percutaneous revascularization of the graft itself, particularly if the occlusion is chronic. </p><p>When grafts are occluded, the best treatment is often to go after the native coronary vessel rather than try to recanalize an occluded graft. (See <a class="local">'Indications for repeat revascularization'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Secondary preventive interventions, such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and statin, achieving blood pressure goal, avoidance of smoking, and the control of serum glucose in patients with diabetes, are recommended for all patients with coronary heart disease (CHD). (See  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>Antiplatelet agents and statins are of proven efficacy for the prevention of saphenous vein graft (SVG) stenosis. (See <a class="local">'Antiplatelet agents'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Antiplatelet agents</span><span class="headingEndMark"> — </span>We recommend that among patients not treated with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> before coronary artery bypass graft surgery (CABG), aspirin with or without a loading dose should be started as soon after surgery as possible. The decision of whether to give a loading dose of aspirin may be influenced by clinical factors such as recent acute coronary syndrome or concern about a risk of early graft failure. Low-dose aspirin should be continued indefinitely. </p><p>We do not routinely use dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> plus a P2Y<sub>12 </sub>inhibitor in these patients.</p><p>For patients who are allergic to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, we suggest aspirin desensitization prior to elective CABG. <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">Clopidogrel</a> (300 mg loading six hours after surgery, followed by a maintenance dose of 75 mg/day) monotherapy is an option for patients who cannot be desensitized. The management of patients allergic to aspirin is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/114687.html" rel="external">"Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions", section on 'Indications for urgent aspirin therapy'</a>.)</p><p>Platelet activation and vein graft thrombosis are thought to be early steps in the process of stenosis and occlusion and forms the rationale for using antiplatelet therapy for prevention. (See  <a class="medical medical_review" href="/d/html/1554.html" rel="external">"Coronary artery bypass graft surgery: Graft choices", section on 'Occlusion within the first 12 to 18 months'</a>.) </p><p><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> given early in the postoperative period improves cardiovascular outcomes after CABG [<a href="#rid1">1</a>] and reduces the incidence of SVG stenosis [<a href="#rid2">2,3</a>]. In a meta-analysis from the Antiplatelet Trialists' Collaboration, low-dose aspirin was associated with improved graft patency, as assessed by coronary angiography, at an average of one year after surgery [<a href="#rid4">4</a>]. The pooled odds reduction for SVG closure was 41 percent (8 percent absolute risk reduction) with low-dose aspirin (75 to 325 mg/day) compared to placebo or control therapy. </p><p>The use of dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> inhibitor (<a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a>) has been evaluated in older small studies that came to differing conclusions regarding the impact of DAPT: </p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 249 patients who were randomly assigned to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> (100 mg/day) and <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> (75 mg/day) or to aspirin alone prior to CABG, the rate of vein graft patency at three months, as assessed by multislice computed tomography angiography, was significantly higher in those treated with dual antiplatelet therapy (92 versus 86 percent) [<a href="#rid5">5</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial of 113 CABG patients who were randomly assigned to either <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 162 mg plus <a class="drug drug_general" data-topicid="8921" href="/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg daily or aspirin 162 mg daily, there was no significant difference in the rate of SVG hyperplasia as determined by intravascular ultrasound at one year [<a href="#rid6">6</a>].</p><p></p><p>A potential benefit from the addition of the more potent P2Y<sub>12</sub> receptor blocker <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> to <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> has been evaluated in two more recent, moderate-sized, randomized trials that evaluated vein graft patency at one year:</p><p class="bulletIndent1"><span class="glyph">●</span>The DACAB trial randomly assigned 500 patients undergoing elective CABG to <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, ticagrelor alone, or aspirin alone within 24 hours [<a href="#rid7">7</a>]. The primary outcome of SVG patency at one year, as determined by multislice computed tomographic angiography or coronary angiography, occurred in 88.7, 82.8, and 76.5 percent of vein grafts in the three groups, respectively. The difference in rate in the ticagrelor plus aspirin and aspirin groups was significant (12.2 percent, 95% CI 5.2-19.2 percent; p&lt;0.001). The rate of SVG occlusion in the aspirin arm of almost 24 percent is much higher than expected and may be due to chance. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The POPular CABG trial randomly assigned 499 aspirin-treated patients with chronic (68 percent) and acute coronary syndromes to <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> or placebo [<a href="#rid8">8</a>]. The primary outcome of 100 percent SVG occlusion as assessed with CCTA occurred in 10.5 and 9.1 percent of the two groups, respectively (odds ratio 1.29, 95% CI 0.73-2.30).</p><p></p><p>The cause(s) of the differing findings in these two trials of <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> are speculative. In the absence of additional evidence to support dual antiplatelet therapy to reduce the risk of the development of SVG stenosis, we do not recommend this therapy. </p><p>A third trial that was stopped prematurely randomly assigned 1859 CABG patients to <a class="drug drug_general" data-topicid="16784" href="/d/drug information/16784.html" rel="external">ticagrelor</a> 90 mg twice daily or <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 100 mg once daily [<a href="#rid9">9</a>]. At 12 months, there was no difference in the rate of a composite outcome of cardiovascular death, MI, repeat revascularization, and stroke (9.7 versus 8.2, respectively; p = 0.89). </p><p>Issues related to the preoperative use of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and platelet P2Y<sub>12</sub> receptor blocker therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1556.html" rel="external">"Coronary artery bypass surgery: Perioperative medical management", section on 'Preoperative aspirin'</a> and  <a class="medical medical_review" href="/d/html/1556.html" rel="external">"Coronary artery bypass surgery: Perioperative medical management", section on 'Platelet P2Y12 receptor blocker therapy'</a>.) </p><p class="headingAnchor" id="H1674146380"><span class="h2">Anticoagulant therapy</span><span class="headingEndMark"> — </span>There is no evidence that long-term anticoagulant therapy, with or without antiplatelet therapy, prevents early graft failure. In the COMPASS-CABG study, a prespecified substudy of the Cardiovascular OutcoMes for People Using Anticoagulation StrategieS (COMPASS) trial of patients with stable disease, 1448 patients were randomly assigned at 4 to 14 days after CABG to <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily plus <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> 100 mg once daily, rivaroxaban 5 mg twice daily, or aspirin 100 mg once daily [<a href="#rid10">10</a>]. Patients underwent computed tomographic angiography at a mean follow-up of 1.13 years to assess graft patency. Neither the combination of rivaroxaban plus aspirin nor rivaroxaban alone, compared with aspirin alone, reduced the risk of graft failure (odds ratio 1.13, 95% CI 0.82-1.57 and 0.95, 95% CI 0.67-1.33, respectively). A lower-than-expected rate of graft failure is an important limitation of this trial. It should be kept in mind that the full COMPASS trial found that anticoagulant therapy lowers the risk of cardiovascular death, myocardial infarction, or stroke in patients with stable coronary artery disease and is discussed separately. (See  <a class="medical medical_review" href="/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Anticoagulant therapy'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Statins</span><span class="headingEndMark"> — </span>− In addition to improvements lowering the risk of death and myocardial infarction, lipid-lowering also may protect against SVG stenosis (see  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>). This was illustrated in the Post Coronary Artery Bypass Graft Trial, which evaluated 1351 patients with serum LDL cholesterol concentrations between 130 and 175 mg/dL (3.4 to 4.5 mmol/L) and at least one patent vein graft documented on angiography performed one to 11 years after CABG [<a href="#rid11">11-13</a>]. Patients were randomly assigned to receive aggressive therapy with <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a> and, if needed, <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> to reduce low density lipoprotein cholesterol to less than 100 mg/dL (2.6 mmol/L) or to moderate therapy, which resulted in levels of approximately 134 mg/dL (3.5 mmol/L). After about four years, aggressive therapy was associated with a lower percentage of grafts showing progression of atherosclerosis (27 versus 39 percent).</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most patients with saphenous vein graft (SVG) stenosis present with recurrent angina. (See  <a class="medical medical_review" href="/d/html/1588.html" rel="external">"Late recurrent angina pectoris after coronary artery bypass graft surgery", section on 'Clinical manifestations'</a>.)</p><p>Less often, patients with SVG stenosis present with an acute myocardial infarction [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/1472.html" rel="external">"Approach to the patient with suspected angina pectoris"</a>.)</p><p class="headingAnchor" id="H246852607"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Saphenous vein graft (SVG) stenosis may be silent or may present as stable angina or an acute coronary syndrome. (See  <a class="medical medical_review" href="/d/html/1588.html" rel="external">"Late recurrent angina pectoris after coronary artery bypass graft surgery", section on 'Diagnosis'</a>.)</p><p>While stress testing with or without imaging may confirm the diagnosis of stable angina, these are not sufficiently reliable to discriminate between ischemia due to native or vein graft disease. The diagnosis of SVG stenosis is usually made at the time of coronary arteriography. However, coronary arteriography is indicated only in those patients who are likely to benefit from repeat revascularization. We uncommonly use intravascular ultrasound (IVUS) or measurement of fractional flow reserve in diseased vein grafts. IVUS is occasionally used to size the vessel. </p><p class="headingAnchor" id="H246852644"><span class="h1">INDICATIONS FOR REPEAT REVASCULARIZATION</span><span class="headingEndMark"> — </span>The broad discussion of the indications for revascularization in patients with angina after coronary artery bypass graft surgery (CABG) is found elsewhere. For patients with saphenous vein graft (SVG) stenosis, revascularization is indicated to improve survival or to improve the quality of life. (See  <a class="medical medical_review" href="/d/html/1588.html" rel="external">"Late recurrent angina pectoris after coronary artery bypass graft surgery", section on 'Indications for revascularization'</a>.) </p><p>Impairment of flow in a SVG <strong>early</strong> (up to 30 days) after surgery is usually attributable to technical failure, a relatively small conduit, or extrinsic factors as the explanation. There is a high likelihood that angina will persist or that acute thrombosis will complicate the stenosis. Such patients should undergo immediate coronary arteriography and percutaneous coronary intervention (PCI) if possible. (See  <a class="medical medical_review" href="/d/html/1554.html" rel="external">"Coronary artery bypass graft surgery: Graft choices", section on 'Early occlusion'</a> and  <a class="medical medical_review" href="/d/html/1584.html" rel="external">"Early cardiac complications of coronary artery bypass graft surgery", section on 'Early graft occlusion'</a>.) </p><p>Although most patients with recurrent angina due to SVG stenosis <strong>after 30 days</strong> can have marked improvement in symptoms with antianginal medical therapy, catheterization should be performed at the earliest signs of recurrent ischemia in most patients to detect critical graft lesions that can be treated before irreversible loss of graft function. Stenoses in these vessels can progress rapidly to total thrombotic occlusion [<a href="#rid16">16</a>]. A heavy thrombus burden in an SVG markedly increases the difficulty in obtaining a satisfactory result using a catheter technique.</p><p>We suggest repeat revascularization for the following groups of stable patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Those for whom revascularization is likely to improve survival. Similar to patients who have not previously undergone CABG, this benefit is likely limited to patients with obstruction of blood flow to the proximal left anterior descending artery (LAD) territory and demonstrable extensive anterior ischemia on noninvasive testing or significant disease in multiple other vessels. (See  <a class="medical medical_review" href="/d/html/1544.html" rel="external">"Management of significant proximal left anterior descending coronary artery disease", section on 'Indications for revascularization'</a>.)</p><p></p><p class="bulletIndent1">The lack of mortality benefit of revascularization in patients without significant proximal LAD obstruction was demonstrated in an observational study of over 4600 patients with prior CABG who had a patent left internal thoracic artery (LITA) bypass graft to the LAD but significant disease in another territory [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with bothersome angina after a trial of medical therapy. Revascularization may be undertaken if there is a reasonable likelihood of procedural success and the patient understands the possibility of recurrent angina. Our threshold for recommending revascularization is somewhat lower in these patients compared to those with native disease, as saphenous vein graft lesions may be at higher risk for acute occlusion with progression. </p><p></p><p>We do not perform PCI of chronic totally occluded vein grafts due to a lower success rate and a high rate of complication.</p><p class="headingAnchor" id="H6"><span class="h2">Percutaneous coronary intervention versus repeat coronary artery bypass graft surgery</span><span class="headingEndMark"> — </span>Most patients in whom there is an indication for repeat revascularization undergo PCI with stenting. Repeat CABG is not optimal since many patients who develop graft disease are poor candidates for surgery because they are older, more likely to have comorbid illnesses, and are at risk for increased morbidity compared to their first bypass surgery. Furthermore, reoperation is generally associated with less complete revascularization and control of symptoms when compared to the first procedure. In addition, repeat CABG is associated with an increase in in-hospital mortality compared to PCI (6 to 9 versus ≤0.5 percent overall and 11.2 versus 1.6 percent in diabetics). On the other hand, the requirement for subsequent revascularization is greater with PCI and no difference has been detected in long-term survival with the two approaches. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1588.html" rel="external">"Late recurrent angina pectoris after coronary artery bypass graft surgery", section on 'Indications for revascularization'</a>.)</p><p class="headingAnchor" id="H503495207"><span class="h2">Recommendations of others</span><span class="headingEndMark"> — </span>Our approach to revascularization in patients with prior CABG is similar to that found in the 2011 American College of Cardiology Foundation/American Heart Association/Society for Cardiovascular Angiography and Interventions guideline for PCI [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H8"><span class="h1">OUTCOMES WITH PCI</span><span class="headingEndMark"> — </span>Since saphenous vein grafts (SVGs) lack side branches, distal occlusion results in stasis and thrombus formation throughout the graft, which makes percutaneous coronary intervention (PCI) more difficult [<a href="#rid19">19</a>]. Thus, as with bypass surgery, outcomes after PCI for SVG stenosis are worse than in native vessels [<a href="#rid19">19</a>]. This was illustrated in a pooled analysis of five randomized glycoprotein (GP) IIb/IIIa inhibitor trials in which PCI for SVG stenosis was associated with significant increases in mortality at both 30 days (2.1 versus 1.0 percent compared to PCI in native vessels) and six months (4.7 versus 2.0 percent) [<a href="#rid20">20</a>]. </p><p>In a large observational series evaluating the outcomes with these procedures, the in-hospital incidence of and risk factors for a major cardiac event after any PCI were evaluated in 1062 patients with SVG stenosis who were followed for three years [<a href="#rid21">21</a>]. The patients were treated with percutaneous transluminal coronary angioplasty (PTCA) alone (42 percent), laser or atherectomy (16 percent), or stenting (42 percent). The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of in-hospital major adverse cardiac events was 13 percent; death occurred in 8 percent, myocardial infarction (MI) in 2 percent, and bypass surgery was performed in 3 percent. Predictors of an in-hospital event were a restenotic lesion, unstable angina, and heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Late major coronary events occurred in 54 percent of patients and included death in 9 percent, MI in 9 percent, and target vessel revascularization (TVR) in 36 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiographic restenosis occurred significantly less often in stented grafts (29 versus 43 percent in nonstented grafts). However, there was no event-free or survival benefit with stenting, due at least in part to progressive disease at nonstented sites.</p><p></p><p>Because of the increase in risk with PCI of a totally occluded SVG, it has been suggested that attention be paid to the risk/benefit ratio in such patients and that, if possible, an attempt should be made to recanalize the underlying native coronary artery rather than the vein graft [<a href="#rid19">19</a>]. If this is not possible, medical therapy rather than PCI should initially be tried unless the patient has symptoms that interfere with the quality of life or a large amount of myocardium at risk.</p><p>Elective stent placement for vein graft disease may reduce the long-term incidence of restenosis, as it does in native coronary arteries. (See  <a class="medical medical_review" href="/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a>.)</p><p>Similar to the native circulation, stenting has replaced balloon angioplasty in the setting, due in large part to lower rates of restenosis [<a href="#rid21">21-24</a>].</p><p>Adverse events and durability after PCI for SVG stenosis are worse than in native vessels. A pooled analysis of five randomized GP IIb/IIIa inhibitor trials found that PCI for SVG stenosis was associated with significantly higher mortality compared with PCI for native disease at both 30 days (2.1 versus 1.0 percent) and six months (4.7 versus 2.0 percent) [<a href="#rid20">20</a>]. In an observational study of 175 patients, poorer overall and event-free survival persisted in patients with SVG disease at five years [<a href="#rid25">25</a>]. The increased need for repeat revascularization was primarily due to progression of disease at other sites.</p><p>Restenosis requiring repeat revascularization remains an important problem. It is less frequent with stenting compared with angioplasty. There have been conflicting reports of benefit of DES versus BMS, although we use DES in most cases. (See  <a class="medical medical_review" href="/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a> and <a class="local">'Outcome by stent type'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Initial observational studies found a 17 to 30 percent restenosis rate for stented vein grafts [<a href="#rid24">24,26,27</a>]. These values are lower than the 40 to 45 percent seen in historical controls treated by other means such as balloon angioplasty and atherectomy [<a href="#rid23">23,24</a>]. The subacute thrombosis rate is very low (about 1 to 2 percent), a reflection of the usually larger luminal diameters in vein grafts than in native coronary arteries [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/d/html/87310.html" rel="external">"Coronary artery stent thrombosis: Clinical presentation and management"</a>.) </p><p>Predictors for restenosis include a restenotic lesion, smaller reference vessel size, higher percent post-stent diameter stenosis, use of long or multiple stenoses, and stenosis at the coronary or aortic anastomosis [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/d/html/1587.html" rel="external">"Intracoronary stent restenosis"</a>.) </p><p>Although data are limited, the rate of restenosis at this site appears to be lower than those at the aorto-ostial site or the shaft portion of the vein graft. In a review of 182 such patients who underwent either PTCA or stenting, the in-hospital outcome was the same for both procedures, and the procedural success rate was 98 percent with major ischemic complications occurring in 1 percent [<a href="#rid29">29</a>]. After an average follow-up of 17 months, the mortality and ST elevation MI (STEMI) rates were the same with both procedures (12 versus 13 percent and 1 versus 0 percent); however, there was a trend toward a higher rate of target lesion revascularization with PTCA (25 versus 14 percent).</p><p>The outcome of SVG stenting is also worse in patients with diabetes, who have higher rates of in-hospital mortality and target lesion revascularization at one year, and a lower rate of overall cardiac event-free survival at one year [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus"</a>.)</p><p>If PCI is performed, stenting is preferred to balloon angioplasty (without stenting), as the latter is associated with high rates of restenosis [<a href="#rid21">21,22</a>]. </p><p class="headingAnchor" id="H336286414"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Coronary embolization of atherothrombotic debris, resulting in elevated cardiac enzymes and an STEMI or non-ST elevation MI (NSTEMI) during catheter intervention, is a more common problem after PCI in SVGs [<a href="#rid19">19</a>]. A possible explanation is that atherosclerotic plaques in SVGs are softer, and more friable, and more commonly associated with thrombus and platelet activation compared to plaques in native coronary arteries [<a href="#rid31">31</a>]. Plaque debris can be retrieved and distal embolization minimized after PCI with an embolic protection device, leading to a reduction in both MI and no-reflow (microvascular dysfunction). (See <a class="local">'Embolic protection devices'</a> below.) </p><p class="headingAnchor" id="H16"><span class="h2">Patients with ST-elevation myocardial infarction</span><span class="headingEndMark"> — </span>Primary PCI is usually the preferred therapy in patients with an STEMI. There are limited data on the efficacy of this modality in patients with SVG lesions. In one study of 370 patients who underwent primary or rescue PTCA, 21 (5.7 percent) were performed on SVGs, with a stent implanted in 14 [<a href="#rid15">15</a>]. Flow was established in 86 percent of patients, but TIMI grade 3 was restored in only 48 percent. Distal embolization and no-reflow occurred in 57 and 71 percent, respectively. The in-hospital mortality was 19 percent and, at six months, the rate of survival free of death, repeat target vessel revascularization, or MI was 55 percent. These results were worse when compared to a parallel group of patients undergoing primary PCI of a native coronary artery. (See  <a class="medical medical_review" href="/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a>.)</p><p class="headingAnchor" id="H348933422"><span class="h2">Outcome by stent type</span><span class="headingEndMark"> — </span>Drug-eluting stents (DES) are preferred to bare metal stents (BMS) in native coronary arterial lesions because their use is associated with a marked reduction in the incidence of restenosis and target vessel revascularization. However, the optimal stent choice for SVG stenosis is not known. (See  <a class="medical medical_review" href="/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a>.)</p><p>Evidence suggests that current generation DES and BMS perform comparably in SVG. In the DIVA trial, 599 patients (predominantly men) were randomly assigned to everolimus- or zotarolimus-eluting stents or BMS [<a href="#rid32">32</a>]. At 12 months, the rate of the primary outcome of target vessel failure, a composite of cardiac death, target vessel MI, or target vessel revascularization, was similar in the two groups (17 versus 19 percent; adjusted hazard ratio 0.92, 95% CI 0.63-1.34). However, the study has limitations, including early termination, male predominance, and absence of double-blind randomization. </p><p>Considering the outcomes, as well as the limitations of DIVA, we prefer DES to BMS for SVG stenosis. The lack of difference may be related to disease progression rather than absence of restenosis benefit. </p><p>In prior, generally small studies that also had methodologic limitations, comparing DES with BMS provided conflicting information regarding clinical outcomes. Observational studies suggested that DES have a similar benefit compared with BMS in diseased SVGs [<a href="#rid33">33-35</a>]. Small randomized trials come to differing conclusions with most showing benefit (lower rates of angiographic in-stent restenosis) [<a href="#rid36">36-38</a>] from early generation DES and one not [<a href="#rid39">39</a>]. </p><p>In addition, there is some evidence that newer generation DES perform well when used to treat vein graft lesions [<a href="#rid40">40-43</a>]. </p><p class="headingAnchor" id="H348933340"><span class="h1">ADJUNCTIVE THERAPIES FOR PERCUTANEOUS CORONARY INTERVENTION</span></p><p class="headingAnchor" id="H21"><span class="h2">Glycoprotein IIb/IIIa inhibitors</span><span class="headingEndMark"> — </span>A thrombus is present in up to 70 percent of occluded saphenous vein grafts (SVGs), and is associated with an increased rate of failure and complications such as abrupt closure, distal embolization, and no reflow. The potential role of platelets in mediating distal embolization and myocardial infarction (MI) has led to interest in the role of antiplatelet agents for preventing these complications. </p><p>A pooled analysis of five randomized trials evaluated the efficacy of intravenous glycoprotein (GP) IIb/IIIa inhibitors during percutaneous coronary intervention (PCI) included 627 patients who underwent PCI for SVG stenosis [<a href="#rid20">20</a>]. There was no evidence of benefit, GP IIb/IIIa inhibitor therapy was associated with nonsignificant trends toward an increase in the triple end point of death, MI, or revascularization at 30 days (16.5 versus 12.6 percent) and at six months (39.4 versus 32.7 percent). As with native coronary lesions, we do not routinely use GP IIb/IIIa in treatment of SVG lesions undergoing PCI.</p><p class="headingAnchor" id="H22"><span class="h2">Atherectomy</span><span class="headingEndMark"> — </span>It has been thought that rotational, directional, or extraction atherectomy might be beneficial in some patients with SVG stenosis, especially when the lesions are densely calcified, aorto-ostial, or at the distal anastomosis site. However, removing graft atheroma using catheter-based techniques has not demonstrated durable value and these procedures are rarely used [<a href="#rid44">44-48</a>]. (See  <a class="medical medical_review" href="/d/html/1567.html" rel="external">"Specialized revascularization devices in the management of coronary heart disease"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Thrombolysis and thrombectomy</span><span class="headingEndMark"> — </span>As atheromas in SVGs are often associated with thrombus, thrombolysis and thrombectomy have been studied as adjunctive therapy for SVG stenosis or occlusion. We do not recommend using thrombolytic therapy to treat SVG thrombus [<a href="#rid49">49</a>]. Catheter-based thrombectomy is an alternative to pharmacologic thrombolysis. None of the devices that can mechanically aspirate thrombus have been shown to improve clinically important outcomes [<a href="#rid48">48-53</a>]. These devices should rarely be used in this setting. For example, we occasionally use the AngioJet device for cases with extremely large clot burden.</p><p class="headingAnchor" id="H24"><span class="h2">Embolic protection devices</span><span class="headingEndMark"> — </span>Our current practice is to use embolic protection devices (EPDs) routinely for all SVG lesions that are (technically) amenable to a protection device. EPDs trap blood and suspended debris in the body of the SVG during stenting, allowing their evacuation before normal flow is restored [<a href="#rid54">54</a>]. Studies with these devices have shown that large quantities of atheroembolic debris are liberated during PCI [<a href="#rid54">54-57</a>]. The aspirate also contains vasoactive substances that can contribute to impaired microvascular perfusion [<a href="#rid58">58</a>].</p><p>A review of early results with the FilterWire EX system highlighted the importance of anatomic, device-specific, and operator-related factors (eg, lack of optimal filter apposition against the SVG wall and an excessively distal lesion resulting in incomplete filter opening or unprotected native side branches) in the attainment of maximal efficacy. Operator attention to these factors reduced the 30-day incidence of adverse events, primarily periprocedural MI, from 21.3 to 11.3 percent [<a href="#rid59">59</a>].</p><p>The FIRE trial compared the PercuSurge GuardWire and the FilterWire EX system in 651 patients undergoing SVG stenting. Initial procedural success was excellent for both devices (97 and 96 percent, respectively). At 30 days, the composite end point of death, MI, or target vessel revascularization was comparable for the GuardWire and the FilterWire (11.6 and 9.9 percent) [<a href="#rid60">60</a>]. The outcomes in terms of the composite end point remained comparable at six months but an additional 10 percent of patients had a new event (21.9 versus 19.3 percent overall) [<a href="#rid61">61</a>]. Target vessel revascularization was required in 9.1 percent.</p><p>The GuardWire is no longer commercially available. Other filter devices have demonstrated similar outcomes as the FilterWire EX and are commercially available.</p><p>A separate issue is the efficacy of distal embolic protection devices in patients with in-stent restenosis in SVGs. The lesion in this setting primarily consists of neointimal proliferation and might be expected to have a lower embolic potential. Observations in 54 consecutive patients who underwent PCI for in-stent restenosis in SVGs without a distal embolic protection device are consistent with this hypothesis [<a href="#rid62">62</a>]. There were no episodes of no-reflow or slow flow during the procedure and no procedure-related MIs. More data are needed to determine the generalizability of these findings.</p><p>Taken together, the above trials have demonstrated the utility of distal embolic protection devices to minimize the adverse effect of downstream debris and thereby improve outcomes in PCI for SVG stenosis. Although these devices have become the standard of care in many laboratories, they are currently underutilized in SVG interventions [<a href="#rid57">57,63</a>].</p><p>Limitations of distal protection devices include passage of the device across a stenotic lesion before distal protection is in place, occlusion of distal filters with debris, failure to prevent the movement of toxic soluble mediators into the distal myocardium, and inability to use the device in distal lesions. These limitations and others have led to the development of a variety of other distal embolic protection devices, proximal occlusion devices, and local plaque trapping devices [<a href="#rid57">57,63,64</a>], although most are no longer available for commercial use. In our laboratory, we use the Spider filter distal protection device, which offers the advantage of allowing lesion crossing with a usual guidewire. </p><p class="headingAnchor" id="H28"><span class="h2">Intracoronary vasodilators</span><span class="headingEndMark"> — </span>Some operators recommend prophylactic use of intracoronary vasodilators as an alternative to EPDs. The evidence to do so is limited. In one study, 83 SVG PCI procedures (average graft age 12 years) were performed in 69 patients who received <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a> (200 to 300 micrograms) delivered via the SVG immediately prior to direct stenting [<a href="#rid65">65</a>]. MI, defined as creatine kinase MB fraction &gt;3 times normal, occurred in three (4.4 percent) patients. These results have to be interpreted with caution given the small nonrandomized sample size at a single center. </p><p class="headingAnchor" id="H2197111795"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119298.html" rel="external">"Society guideline links: Coronary artery bypass graft surgery"</a>.)</p><p class="headingAnchor" id="H23561584"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16429.html" rel="external">"Patient education: Recovery after coronary artery bypass graft surgery (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/3432.html" rel="external">"Patient education: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H284174286"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong>– Aggressive secondary preventative interventions, such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and statin use, achieving blood pressure goal, avoidance of smoking, and the control of serum glucose in patients with diabetes, are recommended in all patients with coronary heart disease, including those who have undergone coronary artery bypass graft (CABG) surgery, to improve cardiovascular outcomes. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– Saphenous vein graft (SVG) stenosis often presents with recurrent angina. However, the cause of angina in patients with SVGs depends in part upon the time after surgery when symptoms are first noted. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of procedure </strong>– Although most patients with recurrent angina due to SVG stenosis can be managed medically, coronary arteriography should be performed at the earliest symptoms or signs of recurrent ischemia to detect critical graft lesions that can be treated before irreversible loss of the graft. (See <a class="local">'Percutaneous coronary intervention versus repeat coronary artery bypass graft surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– Percutaneous coronary intervention (PCI) is preferred to repeat CABG in most patients with recurrent angina, in part due to the increased risks associated with the latter. Factors that might allow for consideration of CABG include<strong> </strong>low anticipated success rate of PCI, quality of the distal vessels, and whether the graft to the proximal left anterior descending coronary artery is involved. (See <a class="local">'Outcomes with PCI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Embolic protection </strong>– Use of distal embolic protection devices should be considered to minimize the adverse effect of downstream debris and thereby improve outcomes in PCI for SVG stenosis. (See <a class="local">'Embolic protection devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of stent </strong>– Drug-eluting stents should be chosen in preference to bare-metal stents when the risk for restenosis outweighs other risks and the patient is able to be compliant with a longer period of dual antiplatelet therapy. (See  <a class="medical medical_review" href="/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a> and <a class="local">'Outcome by stent type'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes after percutaneous coronary intervention </strong>–<strong> </strong>When approaching a patient with recurrent ischemia due to disease in a bypass graft for whom PCI is indicated, an attempt should be made to revascularize the native vessels(s) if technically feasible. (See <a class="local">'Outcomes with PCI'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mangano DT, Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002; 347:1309.</a></li><li><a class="nounderline abstract_t">Sanz G, Pajarón A, Alegría E, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC). Circulation 1990; 82:765.</a></li><li><a class="nounderline abstract_t">Gavaghan TP, Gebski V, Baron DW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. Circulation 1991; 83:1526.</a></li><li><a class="nounderline abstract_t">Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:159.</a></li><li><a class="nounderline abstract_t">Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. J Am Coll Cardiol 2010; 56:1639.</a></li><li><a class="nounderline abstract_t">Kulik A, Le May MR, Voisine P, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010; 122:2680.</a></li><li><a class="nounderline abstract_t">Zhao Q, Zhu Y, Xu Z, et al. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA 2018; 319:1677.</a></li><li><a class="nounderline abstract_t">Willemsen LM, Janssen PWA, Peper J, et al. Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation 2020; 142:1799.</a></li><li><a class="nounderline abstract_t">Schunkert H, Boening A, von Scheidt M, et al. Randomized trial of ticagrelor. Eur Heart J 2019; :2432.</a></li><li><a class="nounderline abstract_t">Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. J Am Coll Cardiol 2019; 73:121.</a></li><li><a class="nounderline abstract_t">Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153.</a></li><li><a class="nounderline abstract_t">Campeau L, Hunninghake DB, Knatterud GL, et al. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. Circulation 1999; 99:3241.</a></li><li><a class="nounderline abstract_t">Knatterud GL, Rosenberg Y, Campeau L, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157.</a></li><li><a class="nounderline abstract_t">Frimerman A, Rechavia E, Eigler N, et al. Long-term follow-up of a high risk cohort after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1997; 30:1277.</a></li><li><a class="nounderline abstract_t">Watson PS, Hadjipetrou P, Cox SV, et al. Angiographic and clinical outcomes following acute infarct angioplasty on saphenous vein grafts. Am J Cardiol 1999; 83:1018.</a></li><li><a class="nounderline abstract_t">Chen L, Théroux P, Lespérance J, et al. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996; 28:1493.</a></li><li><a class="nounderline abstract_t">Subramanian S, Sabik JF 3rd, Houghtaling PL, et al. Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending. Ann Thorac Surg 2009; 87:1392.</a></li><li><a class="nounderline abstract_t">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.</a></li><li><a class="nounderline abstract_t">Stone GW, Reifart NJ, Moussa I, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. Circulation 2005; 112:2530.</a></li><li><a class="nounderline abstract_t">Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 2002; 106:3063.</a></li><li><a class="nounderline abstract_t">Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001; 38:659.</a></li><li><a class="nounderline abstract_t">Savage MP, Douglas JS Jr, Fischman DL, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med 1997; 337:740.</a></li><li><a class="nounderline abstract_t">de Feyter PJ, van Suylen RJ, de Jaegere PP, et al. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol 1993; 21:1539.</a></li><li><a class="nounderline abstract_t">Brener SJ, Ellis SG, Apperson-Hansen C, et al. Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years. Am J Cardiol 1997; 79:13.</a></li><li><a class="nounderline abstract_t">Laham RJ, Carrozza JP, Berger C, et al. Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol 1996; 28:820.</a></li><li><a class="nounderline abstract_t">Piana RN, Moscucci M, Cohen DJ, et al. Palmaz-Schatz stenting for treatment of focal vein graft stenosis: immediate results and long-term outcome. J Am Coll Cardiol 1994; 23:1296.</a></li><li><a class="nounderline abstract_t">Wong SC, Baim DS, Schatz RA, et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group. J Am Coll Cardiol 1995; 26:704.</a></li><li><a class="nounderline abstract_t">Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Risk factors for the development of restenosis following stent implantation of venous bypass grafts. Heart 2001; 85:312.</a></li><li><a class="nounderline abstract_t">Gruberg L, Hong MK, Mehran R, et al. In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. Am J Cardiol 1999; 84:1381.</a></li><li><a class="nounderline abstract_t">Ahmed JM, Hong MK, Mehran R, et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 2000; 36:1186.</a></li><li><a class="nounderline abstract_t">Mautner SL, Mautner GC, Hunsberger SA, Roberts WC. Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men. Am J Cardiol 1992; 70:1380.</a></li><li><a class="nounderline abstract_t">Brilakis ES, Edson R, Bhatt DL, et al. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet 2018; 391:1997.</a></li><li><a class="nounderline abstract_t">Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol 2005; 45:989.</a></li><li><a class="nounderline abstract_t">Tsuchida K, Ong AT, Aoki J, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005; 96:395.</a></li><li><a class="nounderline abstract_t">Brilakis ES, Berger PB. Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot? Catheter Cardiovasc Interv 2008; 72:815.</a></li><li><a class="nounderline abstract_t">Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48:2423.</a></li><li><a class="nounderline abstract_t">Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009; 53:919.</a></li><li><a class="nounderline abstract_t">Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 2011; 378:1071.</a></li><li><a class="nounderline abstract_t">Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 2007; 50:261.</a></li><li><a class="nounderline abstract_t">Wessely R, Marzocchi A, Schwacke H, et al. Long-term follow-up of coronary venous bypass graft lesions treated with a new generation drug-eluting stent with bioabsorbable polymer. J Interv Cardiol 2013; 26:425.</a></li><li><a class="nounderline abstract_t">Badr S, Kitabata H, Dvir D, et al. Optimal revascularization strategies for percutaneous coronary intervention of distal anastomotic lesions after coronary artery bypass surgery. J Interv Cardiol 2013; 26:366.</a></li><li><a class="nounderline abstract_t">Kitabata H, Loh JP, Pendyala LK, et al. Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. Am J Cardiol 2013; 112:61.</a></li><li><a class="nounderline abstract_t">Taniwaki M, Räber L, Magro M, et al. Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. EuroIntervention 2014; 9:1432.</a></li><li><a class="nounderline abstract_t">Holmes DR Jr, Topol EJ, Califf RM, et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. Circulation 1995; 91:1966.</a></li><li><a class="nounderline abstract_t">Waksman R, Weintraub WS, Ghazzal Z, et al. Short- and long-term outcome of narrowed saphenous vein bypass graft: a comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty. Am Heart J 1997; 134:274.</a></li><li><a class="nounderline abstract_t">Thomas WJ, Cowley MJ, Vetrovec GW, et al. Effectiveness of rotational atherectomy in aortocoronary saphenous vein grafts. Am J Cardiol 2000; 86:88.</a></li><li><a class="nounderline abstract_t">Ahmed JM, Hong MK, Mehran R, et al. Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aortoostial lesions: immediate and one-year clinical outcomes. J Am Coll Cardiol 2000; 35:1560.</a></li><li><a class="nounderline abstract_t">Stone GW, Cox DA, Babb J, et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol 2003; 42:2007.</a></li><li><a class="nounderline abstract_t">Teirstein PS, Mann JT 3rd, Cundey PE Jr, et al. Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion. Am J Cardiol 1999; 83:1623.</a></li><li><a class="nounderline abstract_t">Safian RD, Grines CL, May MA, et al. Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts. Circulation 1994; 89:302.</a></li><li><a class="nounderline abstract_t">Meany TB, Leon MB, Kramer BL, et al. Transluminal extraction catheter for the treatment of diseased saphenous vein grafts: a multicenter experience. Cathet Cardiovasc Diagn 1995; 34:112.</a></li><li><a class="nounderline abstract_t">Kuntz RE, Baim DS, Cohen DJ, et al. A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]). Am J Cardiol 2002; 89:326.</a></li><li><a class="nounderline abstract_t">Cohen DJ, Ramee S, Baim DS, et al. Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial. Am Heart J 2001; 142:648.</a></li><li><a class="nounderline abstract_t">Grube E, Gerckens U, Yeung AC, et al. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001; 104:2436.</a></li><li><a class="nounderline abstract_t">Webb JG, Carere RG, Virmani R, et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999; 34:468.</a></li><li><a class="nounderline abstract_t">Grube E, Schofer J Jü, Webb J, et al. Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts. Am J Cardiol 2002; 89:941.</a></li><li><a class="nounderline abstract_t">Mauri L, Cox D, Hermiller J, et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol 2007; 50:1442.</a></li><li><a class="nounderline abstract_t">Leineweber K, Böse D, Vogelsang M, et al. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 2006; 47:981.</a></li><li><a class="nounderline abstract_t">Stone GW, Rogers C, Ramee S, et al. Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. J Am Coll Cardiol 2002; 40:1882.</a></li><li><a class="nounderline abstract_t">Stone GW, Rogers C, Hermiller J, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003; 108:548.</a></li><li><a class="nounderline abstract_t">Halkin A, Masud AZ, Rogers C, et al. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J 2006; 151:915.e1.</a></li><li><a class="nounderline abstract_t">Ashby DT, Dangas G, Aymong EA, et al. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. J Am Coll Cardiol 2003; 41:749.</a></li><li><a class="nounderline abstract_t">Mauri L, Rogers C, Baim DS. Devices for distal protection during percutaneous coronary revascularization. Circulation 2006; 113:2651.</a></li><li><a class="nounderline abstract_t">Gorog DA, Foale RA, Malik I. Distal myocardial protection during percutaneous coronary intervention: when and where? J Am Coll Cardiol 2005; 46:1434.</a></li><li><a class="nounderline abstract_t">Fischell TA, Subraya RG, Ashraf K, et al. "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol 2007; 19:58.</a></li></ol></div><div id="topicVersionRevision">Topic 1565 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12397188" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aspirin and mortality from coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2203555" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022014" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8312766" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21050973" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135365" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710164" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32862716" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Randomized trial of ticagrelor</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30654882" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8992351" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10385497" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10889125" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350927" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term follow-up of a high risk cohort after stent implantation in saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190512" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Angiographic and clinical outcomes following acute infarct angioplasty on saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917263" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19379872" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Decision-making for patients with patent left internal thoracic artery grafts to left anterior descending.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22064601" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230504" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473552" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527613" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9287229" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496517" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024728" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of stenting and balloon angioplasty for narrowings in aortocoronary saphenous vein conduits in place for more than five years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8837554" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176086" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Palmaz-Schatz stenting for treatment of focal vein graft stenosis: immediate results and long-term outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7642863" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. The Palmaz-Schatz Stent Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179274" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors for the development of restenosis following stent implantation of venous bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10606108" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : In-hospital and long-term results of stent deployment compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11028469" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442604" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of composition of atherosclerotic plaques in saphenous veins used as aortocoronary bypass conduits with plaques in native coronary arteries in the same men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759512" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15808752" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16054466" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006238" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Should bare metal or drug-eluting stents be used during PCI of saphenous vein graft lesions: waiting for Godot?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174178" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281920" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21872918" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17631219" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23962106" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term follow-up of coronary venous bypass graft lesions treated with a new generation drug-eluting stent with bioabsorbable polymer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23795684" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Optimal revascularization strategies for percutaneous coronary intervention of distal anastomotic lesions after coronary artery bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23561590" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064377" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7895354" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9313608" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Short- and long-term outcome of narrowed saphenous vein bypass graft: a comparison of Palmaz-Schatz stent, directional coronary atherectomy, and balloon angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10867100" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effectiveness of rotational atherectomy in aortocoronary saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807461" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aortoostial lesions: immediate and one-year clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662267" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392865" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8281662" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Clinical and angiographic results of transluminal extraction coronary atherectomy in saphenous vein bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7788688" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Transluminal extraction catheter for the treatment of diseased saphenous vein grafts: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809436" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A trial comparing rheolytic thrombectomy with intracoronary urokinase for coronary and vein graft thrombus (the Vein Graft AngioJet Study [VeGAS 2]).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579355" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Economic assessment of rheolytic thrombectomy versus intracoronary urokinase for treatment of extensive intracoronary thrombus: Results from a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705821" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440161" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Retrieval and analysis of particulate debris after saphenous vein graft intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11950432" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Evaluation of a balloon occlusion and aspiration system for protection from distal embolization during stenting in saphenous vein grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919563" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16516081" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12446075" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874191" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569562" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628717" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754813" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Devices for distal protection during percutaneous coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226166" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Distal myocardial protection during percutaneous coronary intervention: when and where?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17268038" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : "Pharmacologic" distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
